The Management Team currently consists of the CEO, CFO, CCO, CBO, Head of Manufacturing, Director of HR and General Counsel.
The Board of Directors appoints the CEO and decides on the CEO’s remuneration and other benefits. The CEO is responsible for managing and controlling the Company’s business and day-to-day operations with the aim of securing significant, sustained increase in the value of the company for its shareholders in line with Nanoform’s strategy.
The CEO prepares matters for decision by the Board of Directors and implements the decisions of the Board. The CEO reports to the Board of Directors.
Edward Hæggström
Edward Hæggström
Born 1969. Finnish citizen. Co-founder of Nanoform, CEO and a member of the Management Team since 2015.
Education:Ph.D. degree in applied physics from the University of Helsinki and a Master of Business Administration degree in innovation management from Helsinki University of Technology.
Experience:Dr. Hæggström has, among others, been a professor at the University of Helsinki and Head of the Electronics Research Laboratory within the Department of Physics. He has previously held the role of visiting professor of physics at Harvard Medical School, visiting scholar (assistant professor) of physics at Stanford University and project leader at the CERN.
Other current positions of trust:Dr. Hæggström is scientific advisor and the Chairman of the Board of Directors of GlucoModicum Oy.
Holdings in the company:5,409,405 shares and 0 stock options, entitling to same amount of shares in the company.
Albert Hæggström
Albert Hæggström
Born 1971. Finnish citizen. Member of the Board of Directors since 2015, CFO and a member of the Management Team since 2018. Not independent of the company nor significant shareholders.
Education:
Bachelor of Science degree in economics from Hanken School of Economics in Helsinki.
Experience:
Mr. Hæggström has more than 20 years’ experience within finance and investing. Prior roles include senior positions at Alfred Berg, BNP Paribas, Nordea and SEB.
Other current positions of trust:
Mr. Hæggström is CFO and a member of the Management Team of Nanoform.
Holdings in the company:
701,135 shares and 400,000 stock options, entitling to same amount of shares in the company.
Antonio Da Silva
Antonio Da Silva
Born 1974. Nationality – Portuguese. Nanoform’s Chief of Business Operations and a member of the Management Team since January 2023.
Education:Degree in Chemistry from Lisbon University, Faculty of Sciences, Master degree in Quality from the University Aberta of Lisbon.
Experience:Antonio da Silva has an extensive background in the CDMO and particle engineering space, having worked for 19 years at Hovione, where he took part in several pharmaceutical product launches. Antonio has been with Nanoform since 2019 when he joined as Director, Quality Control.
Other current positions of trust:[-]
Holdings in the company:24,500 shares and 121,000 stock options, entitling to same amount of shares in the company.
Christian Jones
Christian Jones
Born 1980. British citizen. Chief Commercial Officer and a member of the Management Team since 2018.
Education: Master of Chemistry degree from the University of Leeds. Fellow of the Royal Society of Chemistry.
Experience: Mr. Jones has served as Commercial Director, Innovator Pharma Products and Solutions at Johnson Matthey Plc and was a member of the Senior Leadership Team for the Global Health Sector. Prior to this he was Head of Asia Pacific Sales and member of the Senior Leadership Team at Dr. Reddy’s Global Custom Pharma Solutions business after holding the roles of Associate Director and Manager of Sales and Business Development, Europe. His first commercial role was at Prosonix Ltd, where he led global business development for their proprietary particle engineering technology. Prosonix was later sold to Circassia for £100M.
Other current positions of trust: Mr. Jones is a Member of the Industry and Technology Division Council for the Royal Society of Chemistry and serves on the Advisory Board of Pharma Integrates and Bio Integrates Conferences.
Holdings in the company: 300,000 stock options, entitling to same amount of shares in the company.
David Rowe
David Rowe
Born 1967. British citizen. Head of Manufacturing and a member of the Management Team since 2019.
Education:Ph.D. degree in Chemistry from the University of Edinburgh.
Experience:Dr. Rowe has held several positions at GlaxoSmithKline plc including Particle Size Reduction Lead, Platform Expert in the Size Reduction Centre of Excellence, Platform Expert in Micronization & Blending Technologies, Operations Support Manager, Production Projects Manager, Production Team Manager, Improvement Support Manager and Process Chemist at GlaxoSmithKline plc.
Other current positions of trust:[-]
Holdings in the company:290,000 stock options, entitling to same amount of shares in the company.
Johanna Tuomisto
Johanna Tuomisto
Born 1966. Finnish citizen. Director of Human Resources at Nanoform and member of the Management Team since 2021.
Education:Master of Laws (LL.M.) degree from the University of Helsinki, Certified Business Coach.
Experience:Mrs Tuomisto held the position of HR Director, Finland at Thermo Fisher Scientific for over 5 years. She has also previously served as Senior Vice President, Administration at Finnvera Oyj, and as Legal & HR Director and Partner at Evli Bank Plc, among other roles.
Other current positions of trust:[-]
Holdings in the company:50,000 stock options, entitling to same amount of shares in the company.
Peter Hänninen
Peter Hänninen
Born 1988. Nationality – Finnish citizen. Nanoform’s General Counsel and member of the Management Team since September 2020.
Education:Master of Law degree from the University of Helsinki.
Experience:Peter Hänninen has previously served as an attorney in private practice with Borenius Attorneys. In this role, he focused on advising clients in technology, data protection, and general corporate law, with a particular focus on the life science and healthtech sectors. He also held the position of Legal Counsel at the University of Helsinki.
Other current positions of trust:Peter Hänninen has been a Secretary of the Board of Directors at Nanoform since 2015 and a Member of the Board of Directors at Do Company Oy since 2019.
Holdings in the company:103,125 shares and 230,000 stock options, entitlement to an equal amount of shares in the company.